Lab Sciences
Top stories summarized by our editors
12/6/2019

The National Comprehensive Cancer Network has published new clinical practice guidelines for evaluation of patients who before hematopoietic cell transplantation. The document also includes a treatment algorithm and addresses identification and management of acute and chronic graft-versus-host disease.

Full Story:
Targeted Oncology
12/6/2019

The World Health Organization reported Thursday that at least 5,000 people have died from a measles epidemic this year in the Democratic Republic of Congo, many of them children. Factors such as high malnutrition levels and low immunization rates have contributed to the spread of the disease.

Full Story:
Reuters
12/6/2019

The global vaccine alliance GAVI will stockpile 500,000 doses of Merck's Ervebo Ebola vaccine for future outbreaks. Lower- and middle-income countries will have free access to the stockpile, but other countries must reimburse the vaccine's cost to GAVI.

Full Story:
Reuters
12/6/2019

Regeneron Pharmaceuticals unveiled topline data from a midstage trial assessing its candidate REGN3918, or pozelimab, as a treatment for paroxysmal nocturnal hemoglobinuria. Results showed that after being treated once a week, patients' lactate dehydrogenase levels returned to normal by the eighth week.

Full Story:
Seeking Alpha
12/5/2019

The World Health Organization released a report Wednesday that showed the fight against malaria has stalled due to a lack of new funding to support initiatives to counter the mosquito-borne disease. The report called on stakeholders to do more, noting that half of people around the world are at risk of contracting malaria and reductions in infections and mortality have declined more slowly in recent years.

Full Story:
Reuters
12/5/2019

The CDC's most recent Antibiotic Resistance Threats Report says drug-resistant infections kill 35,000 people in the US annually, and although the US has achieved an 18% reduction in mortality associated with these infections, challenges remain, write HHS Secretary Alex Azar and CDC Director Robert Redfield. "The very nature of antibiotic resistance means that new threats are constantly emerging," they write.

12/5/2019

Omeros has released data from a midstage trial assessing OMS721, or narsoplimab, for treatment of thrombotic microangiopathy, a potentially deadly complication of hematopoietic stem cell transplant. Fifty-six percent of patients treated with at least one dose of narsoplimab achieved complete responder status, along with 68% of those treated four weeks or more.

Full Story:
Seeking Alpha
12/4/2019

Thirty-seven percent of US adults have no plans to be vaccinated against influenza this season because they worry about the side effects, they think the vaccine is ineffective or they mistakenly think they might get the flu from the vaccine itself, according to a survey conducted by NORC at the University of Chicago. The CDC recommends annual vaccines for those 6 months and older, and as of early last month, 44% percent of adults said they had gotten the vaccine, and 18% had plans to do so.

Full Story:
The Hill
12/4/2019

Color, which offers population health testing services, is partnering with Vicinity and the Teamsters Health and Welfare Fund of Philadelphia to offer clinical genomic testing and related services to members and dependents of the Fund. "This program gives participating members in-depth knowledge about their hereditary risk and provides information to help them make informed medical and lifestyle decisions," said Maria Scheeler, the Fund's executive director.

Full Story:
Clinical OMICs
12/4/2019

Indivumed will collaborate with Biognosys to add proteomic and phosphoproteomic data from Biognosys' proteomics technology to its IndivuType multi-omics cancer database. "Proteomics and phosphoproteomics play a crucial role in understanding cancer biology and adding Biognosys' technology to the IndivuType multi-omics profile will enable relevant discoveries in our collaborations with pharma and biotech," said Indivumed CEO Hartmut Juhl.

Full Story:
Clinical OMICs
More Summaries:
Indivumed